Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 234-390-0 | CAS number: 11138-47-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1979
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Study well documented, meets generally accepted scientific principles, acceptable for assessment There are no specific ADME studies available. In a study with human volunteers, absorption of sodium perborate monohydrate from a mouthwash solution ("Bocosept") by the oral mucosa or the gastrointestinal tract was tested
Data source
Reference
- Reference Type:
- publication
- Title:
- Absorption of boron after mouthwash treatment with Bocosept
- Author:
- Edwall L, Karlen B & Rosen A
- Year:
- 1 979
- Bibliographic source:
- Europ J clin Pharmacol 15, 417 - 420
Materials and methods
- Objective of study:
- absorption
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- Details of this study are given below
- GLP compliance:
- no
Test material
- Reference substance name:
- Sodium perborate monohydrate
- IUPAC Name:
- Sodium perborate monohydrate
- Details on test material:
- Bocosept contains 1200 mg sodium perborate and 500 mg sodium bitartrate per package. The substance is dissolved in a small volume of water, the solution is "circulated" in the mouth for about 3 min and then spat out. Treatment twice daily is recommended.
According to the manufacturer the following reactions take place in an aqueous solution of the preparation:
NaBO3 H2O + 3 H2O <--> NaBO2 + H2O2 + 3 H2O
NaBO2 + H2O <--> NaH2BO3
In the presence of sodium bitartrate different boron compounds can be formed.
Constituent 1
- Radiolabelling:
- no
Test animals
- Species:
- human
Administration / exposure
- Route of administration:
- other: The substance is dissolved in a small volume of water, the solution is "circulated" in the mouth for about 3 min and then spat out
- Vehicle:
- water
- Details on study design:
- The experiments were carried out on 17 subjects with an age of 17 - 56 years. Nine were patients with severe gingivitis (no other known disease), while 8 were healthy.
One-day Studies
One package of Bocosept dissolved in water was administered according to the manufacturer's recommendation to two patients and two healthy volunteers.
The same procedure was repeated immediately after the 1st treatment with 2 patients and 2 healthy volunteers. Blood was collected before and 5, 10, 20, 40, 60, 120, 240 min and 24 hrs after the start of the 1st and 2nd mouthwash. The mouth content was spat out and was analysed for the boron content.
One-week Studies
Mouthwash:
In one series of experiments five patients rinsed their mouth with one dose every morning and evening for 7 days. Blood and urine samples were taken prior to the start of the treatment. Each morning the patient came to the hospital for blood sampling, delivery of the collected 24 hrs urine and for a mouthwash under supervision. After the 7 days of treatment, blood samples were taken and urine was delivered every morning for a further 7 days. One patient was dropped due to lack of co-operation.
Oral ingestion:
Two healthy volunteers swallowed 3 % of a dose of Bocosept (ca. 51 mg) every morning and evening for 7 days. The experimental procedure was the same as described above. Blood and urine analyses were continued for up to 2.5 days after cessation of the intake. - Details on dosing and sampling:
- Assay of boron:
The assay for boron in the samples was on evaporation and ashing of the sample in a platinum crucible, formation of a complex with curcumine, and spectrophotometric measurement of UV absorption
Results and discussion
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Single Mouthwash
Prior to the experiment, mean blood concentration of boron was 0.04 ug/mL. Two min after completion of the mouthwash the concentration was 0.96 ug/mL with reaching a maximum of 0.14 ug/mL after 2 hrs. The highest individual concentration was 0.2 ug/mL, while the mean concentration was 0.07 ug/mL after 24 hrs. There was no difference in blood boron concentration between patients and healthy volunteers. In two patients with acute ulcerative gingivitis and two healthy volunteers who were given two consecutive doses, the shape and maximal level of the blood concentration curves were similar to those in the experiments with one dose. The highest blood concentration was 0.28 ug/mL in one patient with gingivitis. The mean amount of boron that was spat out was 97 % (94 - 101) of the given dose.
Repeated treatment for 7 days
The mean blood concentration of boron prior to the treatment was 0.07 ug/mL and during the week of treatment the mean concentration was 0.15 - 0.2 ug/mL before the morning dose. Two days after completion of the treatment the mean concentration had returned to control levels. During the week of treatment the mean amount of boron excreted in the urine was 6 - 7 mg/24 hrs decreasing to 2 mg/24 hrs two days after completion of the treatment. The mean total amount of boron excreted in urine during the period from commencement of the treatment until the 4th day after discontinuation was 47.5 mg, i.e. 2.8 % of the total amount administered.
In the experiments with subjects ingesting 3 % of one dose in the morning and evening for one week, the blood concentration of boron before the morning dose was 0.09 - 0.16 ug/mL. The urine excretion of boron amounted to 3.3 - 8.6 mg/24 hrs during the first week.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): low bioaccumulation potential based on study results
Healthy volunteers and patients with gingivitis were treated locally with an boron-containing agent. Blood levels and urinary excretion of boron were examined by a spectrophotometric method. The blood levels during a one-week course of treatment showed a low rate of boron accumulation. The highest concentration was about 0.3 ug B/mL.
It seems more likely that the uptake of boron takes place in the intestine after ingestion of residual amounts from the mouth. - Executive summary:
- Healthy volunteers and patients with gingivitis were treated locally with an boron-containing agent. Blood levels and urinary excretion of boron were examined by a spectrophotometric method. The blood levels during a one-week course of treatment showed a low rate of boron accumulation. The highest concentration was about 0.3 ug B/mL. The results are indicating that only a minor amount of boron is absorbed after a mouthwash. This is based on the fact that an appreciable uptake from the oral cavity should be reflected in the blood concentration of boron within the first few minutes, where no such high concentration was observed. In the one week study (swallowing 3 % of a dose of Bocosept [ca. 51 mg]),the blood and urine concentrations were similar compared with those found after the mouthwashes. Therefore it can be concluded that most of the absorption takes part in the gastrointestinal tract. In all experiments blood boron concentrations returned to the initial level within 1 – 2 says after a single mouthwash as well as after completion of prolonged treatment. From these curves a blood half-life of 5 – 10 hrs can be derived and from the observation that the plateau level of boron in blood following long-term administration was reached after only 24 hrs.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
